Markets
MA Stock Indexes
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
Accentia Biopharmaceuticals, Inc. (OP: ABPI)
0.0140 USD  -0.0040 (-22.22%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 24, 2013  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 303,200
Open 0.0141
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0180
Today's Range 0.0119 - 0.0149
52wk Range 0.0110 - 0.2800
Shares Outstanding 89,755,901
Dividend Yield N/A
Top News
More News
Biovest Files Recapitalization Plan to Strengthen Balance Sheet and Advance Commercialization Strategy for BiovaxID™ Cancer Vaccine
March 07, 2013
from Business Wire News Releases
Biovest to Present BiovaxID™ Cancer Vaccine Update at Lymphoma Coalition Patient Advocacy Event prior to ASH Meeting
December 04, 2012
from Business Wire News Releases

More News
Read More
Biovest Conducts Meeting with EMA Advancing Process to Seek EU Approval for Cancer Vaccine
September 20, 2012
from Business Wire News Releases
Biovest Names Lymphoma Key Opinion Leader from MD Anderson Cancer Center to Scientific Advisory Board
September 11, 2012
from Business Wire News Releases
Biovest Conducts End of Phase III Review with FDA of BiovaxID™ as Consolidation Therapy in Non-Hodgkin’s Lymphoma
August 14, 2012
from Business Wire News Releases
Biovest Advances Process Seeking European Marketing Approval for BiovaxID™ Personalized Lymphoma Vaccine
July 30, 2012
from Business Wire News Releases
Max Planck Institute Presents Study Positioning Biovest Bioreactor Systems as Potential Novel Viral Vaccine Manufacturing Platform
July 19, 2012
from Business Wire News Releases
Biovest’s BiovaxID® Lymphoma Vaccine Featured in FierceBiotech Cancer Immunotherapy Special Report
July 18, 2012
from Business Wire News Releases
Biovest’s Eligibility to Seek EU Marketing Approval for its BiovaxID Cancer Vaccine as Orphan Drug Confirmed by EMA
July 12, 2012
from Business Wire News Releases
Biovest Initiates Formal Regulatory Approval Process for BiovaxID® Cancer Vaccine in Europe
June 20, 2012
from Business Wire News Releases
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here